Post-ablation atrial fibrillation recurrence is not a rare edge case: even with pulsed field ablation, the 2023 ADVENT trial showed one-year treatment success at 73.3%, meaning roughly one in four patients still fails. StimCardio Medical’s NeuroPulse pilot, presented as late-breaking clinical science at HRX Live 2026 and simultaneously published in Heart Rhythm, now puts a number on what wrist-worn neuromodulation might add on top of ablation: 90.0% freedom from atrial arrhythmias at six months in the active arm, versus 80.8% with sham.
The trial enrolled 77 adults with paroxysmal or persistent AF, randomized 1:1 to active median nerve stimulation (MNS) or sham, with therapy starting within 48 hours of catheter ablation and continuing for six months. The modified intention-to-treat analysis covered 59 patients after a 60-day blanking period. The freedom-from-arrhythmia gap between arms did not reach statistical significance, but the event count did: 12 recurrent atrial arrhythmia events with MNS versus 28 with sham in the post-blanking sensitivity analysis (p = 0.025). No MNS-related serious adverse events occurred. The logic here is biological, not technical: rather than refining ablation lesion sets, MNS targets peripheral neural pathways involved in autonomic cardiac regulation, an approach that could run in parallel with whatever ablation method an electrophysiologist already uses.
Lead investigator Vivek Y. Reddy of Mount Sinai framed the finding as a signal worth confirming, not a conclusion, and StimCardio says a pivotal trial is next. That sequence matters for interpreting the data. A 77-patient pilot with a 59-patient analysis is powered to detect a signal, not to validate a therapy. The event-count difference is real and statistically supported; the freedom-from-arrhythmia rate difference is directionally consistent but not yet confirmatory. Investors and electrophysiologists should treat these as two separate reads on the same data, because they carry different evidentiary weight.
The device under development, Rhyvive, is still investigational and restricted to investigational use under U.S. law. The practical question the pivotal trial will need to answer is whether the event-count reduction holds at scale across multiple centers, with a population large enough to push the freedom-from-arrhythmia comparison past the significance threshold. That result will determine whether wearable neuromodulation earns a place in post-ablation care protocols or remains a promising pilot-study finding.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
